<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35091878</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-9932</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>AAPS PharmSciTech</Title>
          <ISOAbbreviation>AAPS PharmSciTech</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Development and Validation of HPLC Method for Efinaconazole: Application to Human Nail Permeation Studies.</ArticleTitle>
        <Pagination>
          <StartPage>63</StartPage>
          <MedlinePgn>63</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1208/s12249-021-02196-3</ELocationID>
        <Abstract>
          <AbstractText>Efinaconazole is the first azole derivative approved by FDA for the topical treatment of onychomycosis. The objective of present study was to develop and validate HPLC method for estimation of efinaconazole in ex vivo human nail permeation study samples. The chromatographic analysis was performed on a HPLC system equipped with diode array detector. The efinaconazole and internal standard (IS) were extracted from the human nail samples by using the protein precipitation method. The samples were injected on to 5 μm Polar C<sub>18</sub> 100Å, 4.6 mm × 150 mm column. The mobile phase consisted of 0.01 M potassium dihydrogen phosphate: acetonitrile (36:64) and eluent was monitored at 205 nm. The chromatographic separation of drug and analyte was achieved using isocratic elution at flow rate of 1 mL/min with a total run time of 15 min. The efinaconazole and IS were eluted at 6.4 ± 0.5 and 8.3 ± 0.5 min, respectively. The developed method was validated as per FDA guidelines, and the results met with acceptance criteria. The method developed was specific, and the analyte concentrations were linear at range of 50 to 10000 ng/mL (R<sup>2</sup> ≥ 0.9981). The validated HPLC method was applied for quantifying efinaconazole in human nail permeation study samples. The permeation of efinaconazole was increased by twofolds with Labarfac CC (15135.4 ± 2233.9 ng/cm<sup>2</sup>) compared to formulations containing Transcutol P (6892.0 ± 557.6 ng/cm<sup>2</sup>) and Labrasol (7266.1 ± 790.6 ng/cm<sup>2</sup>). The study results demonstrate that developed efinaconazole HPLC method can be employed for formulation evaluation and clinical studies.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kolimi</LastName>
            <ForeName>Praveen</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shankar</LastName>
            <ForeName>Vijay Kumar</ForeName>
            <Initials>VK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shettar</LastName>
            <ForeName>Abhishek</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rangappa</LastName>
            <ForeName>Srinath</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Repka</LastName>
            <ForeName>Michael A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murthy</LastName>
            <ForeName>S Narasimha</ForeName>
            <Initials>SN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, Oxford, Mississippi, 38677, USA. murthy@olemiss.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Drug Delivery and Biomedical Research, Mahalaxmipuram, Bangalore, India. murthy@olemiss.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>AAPS PharmSciTech</MedlineTA>
        <NlmUniqueID>100960111</NlmUniqueID>
        <ISSNLinking>1530-9932</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J82SB7FXWB</RegistryNumber>
          <NameOfSubstance UI="C431707">efinaconazole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009262" MajorTopicYN="N">Nails</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014009" MajorTopicYN="Y">Onychomycosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="Y">Triazoles</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">HPLC</Keyword>
        <Keyword MajorTopicYN="N">efinaconazole</Keyword>
        <Keyword MajorTopicYN="N">method development and validation</Keyword>
        <Keyword MajorTopicYN="N">nail permeation</Keyword>
        <Keyword MajorTopicYN="N">onychomycosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>5</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35091878</ArticleId>
        <ArticleId IdType="doi">10.1208/s12249-021-02196-3</ArticleId>
        <ArticleId IdType="pii">10.1208/s12249-021-02196-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Monti D, Mazzantini D, Tampucci S, Vecchione A, Celandroni F, Burgalassi S, Ghelardi E. Ciclopirox and efinaconazole transungual permeation, antifungal activity, and proficiency to induce resistance in Trichophyton rubrum. Antimicrob Agents Chemother. 2019;63(10):e00442–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00442-19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipner SR. Pharmacotherapy for onychomycosis: new and emerging treatments. Expert Opin Pharmacother. 2019;20(6):725–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14656566.2019.1571039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta AK, Stec N. Emerging drugs for the treatment of onychomycosis. Expert Opin Emerg Drugs. 2019;24(4):213–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14728214.2019.1685493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol. 2010;28(2):151–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clindermatol.2009.12.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21(6):525–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1203475417716362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jdv.16394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghannoum M, Isham N. Fungal nail infections (onychomycosis): a never-ending story? PLoS Pathog. 2014;10(6):e1004105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1004105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24364524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatt V, Pillai R. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis. J Pharm Sci. 2015;104(7):2177–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.24459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jo Siu WJ, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D, Fothergill A. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.02056-12</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta AK, Venkataraman M, Shear NH, Piguet V. Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis. Dermatol Ther. 2020;33(4):e13613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32418289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vikas A, Rashmin P, Mrunali P, Sandip M, Kaushik T. RP-HPLC method for quantitative estimation of Efinaconazole in topical microemulsion and microemulsion-based-gel formulations and in presence of its degradation products. Microchem J. 2020;155:104753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.microc.2020.104753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patani N, Patel M, Patel R. Development and validation of HPLC methodology for quantitative estimation of Efinaconazole in topical pharmaceutical formulation prepared in-house for the treatment of onychomycosis. Sep Sci Plus. 2020;3(9):375–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sscp.202000019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel RB, Patel MR, Patni NR, Agrawal V. Efinaconazole: DoE-supported development and validation of a quantitative HPTLC method and its application for the assay of drugs in solution and microemulsion-based formulations. Anal Methods. 2020;12(10):1380–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C9AY02599E</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Department of Health and Human Services F and DA. Bioanalytical Method Validation Guidance for Industry. US Dep Heal Hum Serv Food Drug Adm [Internet]. 2018;1–41. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf .</Citation>
        </Reference>
        <Reference>
          <Citation>Police A, Shankar VK, Murthy SN. RP-HPLC method for simultaneous estimation of vigabatrin, gamma-aminobutyric acid and taurine in biological samples. J Chromatogr B. 2018;1076:44–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchromb.2018.01.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar SV, Rudresha G, Gurav S, Zainuddin M, Dewang P, Kethiri RR, Rajagopal S, Mullangi R. Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. Biomed Chromatogr. 2013;27(2):203–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bmc.2776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shankar VK, Wang M, Ajjarapu S, Kolimi P, Avula B, Murthy R, Khan I, Murthy SN. Analysis of docosanol using GC/MS: Method development, validation, and application to ex vivo human skin permeation studies. J Pharm Anal. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Cutrín-Gómez E, Anguiano-Igea S, Delgado-Charro MB, Gómez-Amoza JL, Otero-Espinar FJ. Effect of penetration enhancers on drug nail permeability from cyclodextrin/poloxamer-solublepolypseudorotaxane-based nail lacquers. Pharmaceutics. 2018;10(4):273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics10040273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myoung Y, Choi HK. Permeation of ciclopirox across porcine hoof membrane: effect of pressure sensitive adhesives and vehicles. Eur J Pharm Sci. 2003;20(3):319–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejps.2003.07.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thatai P, Sapra B. Transungual gel of terbinafine hydrochloride for the management of onychomycosis: formulation, optimization, and evaluation. AAPS PharmSciTech. 2017;18(6):2316–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12249-017-0711-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walters KA, Flynn GL, Marvel JR. Physicochemical characterization of the human nail: permeation pattern for water and the homologous alcohols and differences with respect to the stratum corneum. J Pharm Pharmacol. 1983;35(1):28–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2042-7158.1983.tb04258.x</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
